The health journey of NFL legend and University of Colorado head coach Deion Sanders has become more than a personal battle - ...

Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

BCG failure is much less common than previously thought in non-muscle invasive bladder cancer, so is adding a checkpoint ...

Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies.

Merck (MRK) stock is in focus as the company's Keytruda versions win FDA priority review for an expanded indication in ...

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...

Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...

(Reuters) -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor ...

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...

AstraZeneca's Imfinzi with BCG delivers 32% lower recurrence risk in high-risk bladder cancer. Read more here.

Simple hysterectomy may result in little to no difference in the number of deaths from any cause, life expectancy after treatment, deaths from cancer, cancer-free period after treatment, or the rate ...